Literature DB >> 23791462

Fibrosing interstitial pneumonia predicts survival in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD).

Joshua J Solomon1, Jay H Ryu, Henry D Tazelaar, Jeffrey L Myers, Rubin Tuder, Carlyne D Cool, Douglas Curran-Everett, Aryeh Fischer, Jeffrey J Swigris, Kevin K Brown.   

Abstract

BACKGROUND: Rheumatoid arthritis (RA) is a systemic autoimmune disorder with a variety of extra-articular manifestations. The lung is a common target and diffuse parenchymal lung disease can appear as any of the patterns found with idiopathic interstitial pneumonia. Controversy exists as to the prognostic significance of these patterns among patients with RA-ILD.
METHODS: We retrospectively identified 48 patients with a diagnosis of RA-ILD confirmed by surgical lung biopsy. The pathology was reviewed by four expert pulmonary pathologists. We examined survival after stratifying on the presence or absence of fibrotic ILD, and contrasted it with a matched idiopathic pulmonary fibrosis (IPF) population. The Cox proportional hazards model was used to identify independent predictors of survival.
RESULTS: The majority of subjects were male smokers with physiologic restriction. A usual interstitial pneumonia (UIP)-pattern was identified in 31% of subjects. Median survival time for the entire cohort was 1360 days. Subjects with fibrotic ILD had worse survival than subjects with non-fibrotic ILD (log rank p = 0.02). There was no difference in survival between UIP-pattern RA-ILD subjects and IPF controls (log rank p = 0.94). Multivariable analysis revealed that age (hazard ratio [HR] = 1.04, p = 0.01) and fibrosis (HR = 2.1, p = 0.02) were independent predictors of mortality.
CONCLUSIONS: Both cellular and fibrosing ILD patterns are common among RA-ILD patients who undergo surgical lung biopsy. These patients have a shortened survival when compared to the general population and all-comers with RA. Age and the presence of a fibrosing interstitial pneumonia predict shortened survival in these patients. Survival in UIP is similar to matched IPF patients.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Interstitial lung disease; Nonspecific interstitial pneumonia; Rheumatoid arthritis; Usual interstitial pneumonia

Mesh:

Year:  2013        PMID: 23791462     DOI: 10.1016/j.rmed.2013.05.002

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  37 in total

Review 1.  Lung disease in rheumatoid arthritis.

Authors:  Zulma X Yunt; Joshua J Solomon
Journal:  Rheum Dis Clin North Am       Date:  2015-02-03       Impact factor: 2.670

2.  Retrospective study of the clinical characteristics and risk factors of rheumatoid arthritis-associated interstitial lung disease.

Authors:  Yongfeng Zhang; Hongbin Li; Nawei Wu; Xin Dong; Yi Zheng
Journal:  Clin Rheumatol       Date:  2017-02-12       Impact factor: 2.980

3.  Clinical characteristics and survival in idiopathic pulmonary fibrosis and connective tissue disease-associated usual interstitial pneumonia.

Authors:  Esam H Alhamad
Journal:  J Thorac Dis       Date:  2015-03       Impact factor: 2.895

4.  The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.

Authors:  Julie Morisset; Eric Vittinghoff; Bo Young Lee; Roberto Tonelli; Xiaowen Hu; Brett M Elicker; Jay H Ryu; Kirk D Jones; Stefania Cerri; Andreina Manfredi; Marco Sebastiani; Andrew J Gross; Brett Ley; Paul J Wolters; Talmadge E King; Dong Soon Kim; Harold R Collard; Joyce S Lee
Journal:  Respir Med       Date:  2017-04-22       Impact factor: 3.415

5.  Pulmonary function and survival in idiopathic vs secondary usual interstitial pneumonia.

Authors:  Matthew J Strand; David Sprunger; Gregory P Cosgrove; Evans R Fernandez-Perez; Stephen K Frankel; Tristan J Huie; Amy L Olson; Joshua Solomon; Kevin K Brown; Jeffrey J Swigris
Journal:  Chest       Date:  2014-09       Impact factor: 9.410

Review 6.  Interstitial Lung Disease in Elderly Rheumatoid Arthritis Patients.

Authors:  Riccardo Messina; Giuliana Guggino; Alida Benfante; Nicola Scichilone
Journal:  Drugs Aging       Date:  2020-01       Impact factor: 3.923

7.  Outcome Measures for Clinical Trials in Interstitial Lung Diseases.

Authors:  Matthew R Lammi; Robert P Baughman; Surinder S Birring; Anne-Marie Russell; Jay H Ryu; Marybeth Scholand; Oliver Distler; Daphne LeSage; Catherine Sarver; Katerina Antoniou; Kristin B Highland; Otylia Kowal-Bielecka; Joseph A Lasky; Athol U Wells; Lesley Ann Saketkoo
Journal:  Curr Respir Med Rev       Date:  2015

Review 8.  Rheumatoid Arthritis-Associated Interstitial Lung Disease and Idiopathic Pulmonary Fibrosis: Shared Mechanistic and Phenotypic Traits Suggest Overlapping Disease Mechanisms.

Authors:  Francisco Paulin; Tracy J Doyle; Elaine A Fletcher; Dana P Ascherman; Ivan O Rosas
Journal:  Rev Invest Clin       Date:  2015 Sep-Oct       Impact factor: 1.451

9.  African-American race and mortality in interstitial lung disease: a multicentre propensity-matched analysis.

Authors:  Ayodeji Adegunsoye; Justin M Oldham; Shashi K Bellam; Jonathan H Chung; Paul A Chung; Kathleen M Biblowitz; Steven Montner; Cathryn Lee; Scully Hsu; Aliya N Husain; Rekha Vij; Gokhan Mutlu; Imre Noth; Matthew M Churpek; Mary E Strek
Journal:  Eur Respir J       Date:  2018-06-14       Impact factor: 16.671

Review 10.  Interstitial lung disease in patients with rheumatoid arthritis: spontaneous and drug induced.

Authors:  Robert W Hallowell; Maureen R Horton
Journal:  Drugs       Date:  2014-03       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.